AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 251 min read$SLXN

Silexion Therapeutics Corp (SLXN): Submission of Matters to a Vote of Security Holders

Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 23, 2026, Silexion Therapeutics Corp (the “ Company ”) reconvened (for the second time) its extraordinary general meeting (the “ Meeting ”), which had originally been scheduled for September 9, 2026 but

Original reporting
SEC EDGAR 8-K
Published Sep 25, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$SLXN
Neutral
high confidence
Mentioned
$SLXN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SLXNNeutralLow
01

Why it matters

The failed proposals mean no immediate dilution or share consolidation, limiting market impact.

02

Market read

Minimal relevance; the vote outcome does not alter capital structure.

03

What to watch

Possible upcoming financing needs not disclosed.

Relevance 6/10Novelty 4/10Timing: filed Sep 25 2026

Background

SEC Form 8‑K filing reporting the results of an extraordinary shareholders' meeting.

Company-level read

Ticker impact

$SLXNNeutralHigh confidence
Context

Shareholders voted on a capital increase and reverse split; both proposals were rejected.

Expected impact

little to no short-term movement

Evidence & confidence

The vote outcome does not change capital structure, so market reaction is expected to be muted.

Market effects

Sector

None significant for biotech sector.

Regional

Limited to company shareholders.

Global

Low

Counterpoint

What could challenge this read

Potential for future capital raise if shareholder sentiment shifts.

Key entities

  • company
    Silexion Therapeutics Corp

    Biotech firm filing the 8‑K.

Read at source← All news

Related articles

SEP 30
$SLXNMedAI 8/10

Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer Global Phase 2/3 trial evaluates SIL204 in combination with standard chemotherapy in patients with locally advanced pancreatic

SEC EDGAR 8-K2 min
SEP 30
$SLXNMedAI 8/10

Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Silexion Therapeutics (SLXN) dosed the first patient in its Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer. The trial combines SIL204 with standard chemotherapy. The study is being conducted at Tel Aviv Sourasky Medical Center and will expand to other sites in Israel and Germany. SIL204 is administered via a dual-route delivery strategy. The company aims to evaluate the potential of SIL204 to improve patient outcomes.

globenewswire.com2 min
SEP 29
$SLXNMedAI 8/10

Silexion Therapeutics (SLXN) Stock Soars 61% After Hours: Here's What's Going On - Silexion Therapeutics

Silexion Therapeutics (SLXN) shares surged 61% after reporting positive preclinical results for SIL204, its lead cancer therapy. The study showed dose-dependent gene silencing in KRAS-driven cancer cells. The company is advancing clinical trials. SLXN has a $1.43M market cap, down 99.27% over the past year. Shares fell 4.57% to $0.25 during regular trading.

benzinga.com2 min
SEP 28
$SLXNMedAI 8/10

Silexion Advances SIL204 With Positive Findings On Systemic Uptake In KRAS-Driven Cancers

Silexion Therapeutics (SLXN) reported positive findings from a study on SIL204, its RNAi candidate for KRAS-driven cancers. The study showed SIL204 utilizes lipoproteins for cellular delivery and potent gene silencing. The company is advancing SIL204 in a Phase 2/3 trial for pancreatic cancer and continues site initiation and patient screening. SLXN's stock is up 1.84% to $0.26.

rttnews.com2 min